Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Belite Bio, Inc (NASDAQ:BLTE) – HC Wainwright dropped their Q1 2025 earnings estimates for Belite Bio in a report released on Tuesday, March 18th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.37) per share for the quarter, down from their previous estimate of ($0.32). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Belite Bio (NASDAQ:BLTE) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Several other equities analysts have also recently issued reports on the stock. Benchmark boosted their price target on shares of Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a research report on Tuesday, January 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Belite Bio in a research report on Tuesday.

Belite Bio Price Performance

Shares of NASDAQ BLTE opened at $67.28 on Thursday. Belite Bio has a 1 year low of $31.01 and a 1 year high of $86.53. The company’s 50-day moving average is $59.48 and its 200 day moving average is $60.84. The stock has a market capitalization of $2.14 billion, a P/E ratio of -60.61 and a beta of -1.54.

Institutional Investors Weigh In On Belite Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of BLTE. JPMorgan Chase & Co. grew its holdings in Belite Bio by 130.3% in the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company’s stock worth $924,000 after purchasing an additional 8,280 shares during the period. XTX Topco Ltd purchased a new stake in Belite Bio in the third quarter worth about $253,000. Bank of America Corp DE grew its holdings in Belite Bio by 36.4% in the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after purchasing an additional 4,891 shares during the period. State Street Corp lifted its stake in shares of Belite Bio by 28.2% in the third quarter. State Street Corp now owns 20,086 shares of the company’s stock worth $942,000 after buying an additional 4,415 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Belite Bio in the fourth quarter worth approximately $155,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.